Events

Event Archive

Events

Show Filters

Days

Categories

Venues

Organizers

Reset Filters
«
»
  • 04
    04
    August

    1:00 pm-3:00 pm
    08-04-2017
    1st Floor Conference Room, GEHC
    953 Indiana Street, San Francisco, CA 94107, United States

    Gregory S. Naeve, PhD
    Head of External R&D, Pfizer

    To apply for Office Hours, please contact Linda Eng.

    About Gregory S. Naeve
    Dr. Naeve is currently the Head of External R&D for Pfizer’s Cancer Immunotherapy programs. He is also head of global scouting in the Northwest region of North America. In this role Greg is responsible for liaising with Pfizer Scientists to identify and institute strategic partnerships that address internal technology and pipeline needs. Prior to Pfizer he worked as a venture capitalist with the San Francisco-based life science venture fund, The Column Group, a firm focused on creating biotechnology companies to develop novel therapeutics and technologies. Prior to that he was the President and Chief Scientific Officer of Parallax Biosystems, a company he co-founded to develop a molecular detection platform with applications in pre-clinical drug discovery and diagnostics. Before Parallax he held positions at Neurocrine Biosciences and Amgen working to develop new therapies for neurodegenerative disorders. He received his Ph.D. in Biochemistry from the University of Southern California.

  • 10
    10
    August

    12:00 pm-1:00 pm
    08-10-2017
    1st Floor Conference Room, GEHC
    953 Indiana Street, San Francisco, CA 94107, United States

    RSVP

    Lunch Seminar with
    Elton Satusky and Ali Alemozafar

    Elton Satusky and Ali Alemozafar of Wilson Sonsini will present on important corporate and intellectual property topics for startups, including corporate formation and venture financing, and strategies for protecting intellectual property.

  • 11
    11
    August

    12:00 pm-1:00 pm
    08-11-2017
    1st Floor Conference Room, GEHC
    953 Indiana Street, San Francisco, CA 94107, United States

    RSVP
    Frank McCormick, PhD, FRS
    UCSF Helen Diller Family Comprehensive Cancer Center

    KRAS proteins play a major role in human cancer. To target the KRAS protein directly, we have used tethering to identify compounds that covalently bind at two key residues, one which affects KRAS membrane localization, and another at a site unique to KRAS amongst other RAS proteins. We have also screened for molecules that cause allosteric changes in KRAS detected by a novel biophysical technique called Second Harmonic Generation. Dr. McCormick will discuss how these approaches are being developed and prospects for treating cancer using these, and other, KRAS inhibitors.

    Frank McCormick, PhD, FRS, is a Professor at the UCSF Helen Diller Family Comprehensive Cancer Center. Prior to joining the UCSF faculty, Dr. McCormick pursued cancer-related work with several Bay Area biotechnology firms and held positions with Cetus Corporation (Director of Molecular Biology, 1981-1990; Vice President of Research, 1990-1991) and Chiron Corporation, where he was Vice President of Research from 1991 to 1992. In 1992 he founded Onyx Pharmaceuticals, a company dedicated to developing new cancer therapies, and served as its Chief Scientific Officer until 1996. At Onyx Pharmaceuticals, he initiated and led drug discovery efforts that led to the approval of Sorafenib in 2005 for treatment of renal cell cancer, and for liver cancer in 2007, and the approval of ONYX-015 in 2006 in China for treatment of nasopharyngeal cancer. Sorafenib is being tested in multiple indications worldwide. In addition, Dr. McCormick’s group led to the identification of the CDK4 kinase inhibitor, Palbociclib, approved for treating advanced breast cancer. Dr. McCormick’s current research interests center on the fundamental differences between normal and cancer cells that can allow the discovery of novel therapeutic strategies.

    Dr. McCormick holds the David A. Wood Chair of Tumor Biology and Cancer Research at UCSF. Dr. McCormick is the author of over 320 scientific publications and holds more than 20 issued patents. He was Director of the Helen Diller Family Comprehensive Cancer Center from 1997 to 2014. He also served as President, 2012-2013, for the American Association for Cancer Research (AACR). Since 2013 he has taken a leadership role at the Frederick National Lab for Cancer Research, overseeing an NCI supported national effort to develop therapies against Ras-driven cancers. These cancers include most pancreatic cancers, and many colorectal and lung cancers, and are amongst the most difficult cancers to treat.

  • 17
    17
    August

    12:00 pm-1:00 pm
    08-17-2017
    1st Floor Conference Room, GEHC
    953 Indiana Street, San Francisco, CA 94107, United States

    RSVP
    Pierre Tremblay, PhD
    GE Healthcare

    This presentation will cover the latest GEHC chromatography resin portfolio. We will discuss the advantages of the modern bases matrices in the context of improving selectivity and throughput as it relates to process economy. We will also present and discuss approaches to resolve some purification challenges using both PreDictor plates (filter plates) and columns formats.

    Pierre Tremblay has been with GE Healthcare for 15 years but started in protein purification as a graduate student. He supported and then lead the BioProcess courses in the GE portfolio, delivering custom courses at industry and academic sites.

  • 31
    31
    August

    2:00 pm-3:30 pm
    08-31-2017
    1st Floor Conference Room, GEHC
    953 Indiana Street, San Francisco, CA 94107, United States

    RSVP
    From common-but-stubborn ailments like acne to the future of gene therapy or personalized cancer care, the breadth of biotech innovation happening in the Bay Area is vast. All told, the California Life Sciences Association estimates that the sector accounts for some 68,300 jobs in the region and nearly $1 billion in annual venture capital investment.

    To capture a snapshot of the work under way, the Business Times selected seven young scientists and entrepreneurs spanning established drugmakers, startups and academia. Though their interests and backgrounds are varied, they all have one thing in common: each is poised to make a major impact on the future of life sciences.

    Read the complete article at BizJournals

Upcoming Event

  • An Afternoon Tea Party for the Awesome 3 from the Magnificent 7!

    14:00-15:30
    08/31/2017
    1st Floor Conference Room, GEHC
    953 Indiana Street, San Francisco, CA 94107, United States
    RSVP From common-but-stubborn ailments like acne to the future of gene therapy or personalized cancer care, the breadth of biotech innovation happening in the Bay Area is vast. All told, the California Life Sciences Association estimates that the sector accounts for some 68,300 jobs in the region and nearly $1 billion in annual venture capital investment. To capture a snapshot of the work under way, the Business Times selected seven young scientists and entrepreneurs spanning established drugmakers, startups and academia. Though their interests and backgrounds are varied, they all have one thing in common: each is poised to make a major impact on the future of life sciences. Read the complete article at BizJournals

Address

953 Indiana St., San Francisco, CA 94107
Tel: (415)-347-8287
Map

Sign-Up for our Newsletter